Cavtat-Dubrovnik, Croatia
More info
News & events
IPH 1101 in combination with rituximab enters the second part of the Phase I/II trial in fNHL
July 16, 2008
Innate Pharma SA announces today that IPH 1101 in combination with rituximab was authorized to enter the second part of the Phase I/II trial in follicular non-Hodgkin's lymphoma.
Outcome of the AGM that took place on June 27, 2008
July 7, 2008
Innate Pharma SA announces the outcome of its AGM that took place on June 27, 2008, in Marseilles and updates on the divestment process by Novo Nordisk A/S of its rights to IPH 2101.
Total number of shares outstanding and voting rights, as of April 30, 2008
June 16, 2008
Innate Pharma SA has released the total number of shares outstanding and voting rights, as of April 30, 2008.
Innate Pharma will hold its AGM of Shareholders on June 27, 2008, in Marseilles
May 26, 2008
Innate Pharma S.A. will hold its Annual General Meeting of Shareholders on June 27, 2008, in Marseilles, France.
An information meeting open to shareholders, analysts, investors and journalists will be held on the same day and in the same venue.
IPH 2301 enters into regulatory pre-clinical development
May 23, 2008
Innate Pharma SA announces today the entry into regulatory pre-clinical development of IPH 2301, a novel monoclonal antibody targeting NK (Natural Killer) and T cells. It is the first antibody from the NK platform to be developed for the treatment of inflammatory conditions.
Results for Phase IIa study with IPH 1101 in mRCC
May 23, 2008
Innate Pharma SA today announces results for its Phase IIa study with IPH 1101, an agonist of gamma delta T cells, as a second line monotherapy in metastatic renal cell carcinoma.
In connection with this announcement, a conference call was organized on May 23, 2008.